Cancer Prevention Pharmaceuticals, Inc. (CPP) was established to develop products and solutions for people with elevated risk for cancer. The company is initially focused on colon cancer; however, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners.
CPP's founders have pioneered the development and exploitation of key pathways implicated in cancer risk: polyamine synthesis and inflammation. These two processes have long been implicated in cancer development but never successfully utilized—together—to exploit and treat cancer precursors until now. CPP believes that the best way to create and develop prevention therapy is to use a "combination" approach that incorporates the best scientific, drug development, and regulatory tools available.
CPP is currently preparing two FDA registration trials for treating the risk factors of colorectal cancer (CRC) in elevated and high risk groups, including individuals with prior CRC or advanced colorectal adenomas (CRA) and those with genetic risk factors such as familial adenomatous polyposis (FAP). CPP is also supporting a prevention study in neuroblastoma. The company's programs are summarized in the regulatory timeline shown below.
These studies are based on recent successes in a randomized, placebo-controlled clinical trial using combination chemoprevention targeting ademomas which are high risk polyps that are the primary precursor to colon cancer. CPP's agent, CPP-1X, in combination with the non-steroidal anti-inflammatory drug (NSAID) sulindac, reduced the risk of recurrence of all polyps by 70% and reduced the risk of recurrence for advanced and multiple polyps by over 90% as shown in the figure below. These latter classes of polyps are the primary risk factor for colon cancer. In this trial, which evaluated patients with prior sporadic colon polyps, combination chemoprevention for three years with difluoromethylornithine (DFMO), a selective inhibitor of ornithine decarboxylase, and the non-steroidal anti-inflammatory drug (NSAID) sulindac, reduced the risk of recurrence of advanced and multiple polyps by over 90% as shown in the figure below.
UA Spin-off to Test Cancer Prevention . . .
CPP Receives Positive . . .
Success in Clinical Trials . . .
Biotech Firms Get Funding . . .
Tucson Cancer Prevention Firm is BioIndustry Winner . . .
Company Gets U.S. Grant for Research of Cancer Drug . . .
CPP Wins Fast Start Award and Federal Grant . . .